APG-808 is under clinical development by Apogee Therapeutics and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase I drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how APG-808’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APG-808 overview
APG808 is under development for the treatment of inflammatory, unspecified immunological diseases, asthma and chronic obstructive pulmonary disease (COPD). It acts by targeting interleukin 4 receptor subunit alpha (IL-4Ra). It is administered through subcutaneous route.
Apogee Therapeutics overview
Apogee Therapeutics (Apogee) is a clinical-stage biotechnology company. It focuses on the development of differentiated biologics for the treatment of various inflammatory and immune (I&I) diseases. Apogee’s pipeline products include APG777, APG808, APG990, and APG222, that are being developed for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma, and other I&I diseases. Its products span across the healthcare industry, specifically in the treatment of chronic inflammatory skin disorders and progressive respiratory diseases. The company operates in France, Germany, Italy, Japan, the UK, Spain, and the US. Apogee is headquartered in Waltham, Massachusetts, the US.
For a complete picture of APG-808’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
